Brief: Herantis Pharma receives orphan designation of CDNF for treatment of ALS

Herantis Pharma Oyj

29/03/2016 07:01

March 29 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :  
    * Herantis Pharma receives orphan designation of Cerebral 
Dopamine Neurotrophic Factor (CDNF) for treatment of amyotrophic 
lateral sclerosis (ALS) 
 
Source text for Eikon:  ID:nHUG5cSLhB  
Further company coverage:  HRTIS.HE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))